A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20 + indolent NHL: Correlation between clinical responses and AUC pharmacokinetics

PRO131921 is a third-generation, humanized anti-CD20 monoclonal antibody with increased antibody-dependent cytotoxicity and complement-dependent cytotoxicity compared to rituximab. In this phase I study, PRO131921 was administered as a single agent to patients with CD20+, relapsed or refractory, ind...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Immunol
Hlavní autoři: Casulo, Carla, Vose, Julie M., Ho, William Y., Kahl, Brad, Brunvand, Mark, Goy, Andre, Kasamon, Yvette, Cheson, Bruce, Friedberg, Jonathan W.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4348114/
https://ncbi.nlm.nih.gov/pubmed/24928323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clim.2014.06.005
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky